| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
| Targets |
Endogenous Metabolite
|
|---|---|
| ln Vitro |
Methylcobalamin is a synthetic and active form of vitamin B12 that can cross the blood brain barrier without biotransformation, that may be used to treat or prevent vitamin B12 deficiency and its complications. Upon administration, mecobalamin is able to replace endogenous vitamin B12, increase vitamin B12 levels and improve vitamin B12 deficiency. Vitamin B12 is necessary for hematopoiesis, neural metabolism, DNA and RNA production, and carbohydrate, fat, and protein metabolism. It improves iron functions in the metabolic cycle and assists folic acid in choline synthesis. Its metabolism is interconnected with that of folic acid.
|
| ln Vivo |
After 4 weeks, 8 weeks, 3 months and 6 months, the difference of serum Hcy level between the two groups was statistically significant (t = 4.049, 3.896, 6.052, 6.159, respectively. All P <0.05). After the treatment, at 4 weeks, 8 weeks, 3 months and 6 months, the levels of hs-CRP in the treatment group were significantly lower than those in the control group (t = 37.249, 28.376, 26.454, 20.522, respectively. All P <0.01). After 3 months and 6 months, the carotid artery plaques were significantly reduced in the treatment group compared to those in the control group (t = 2.309 and 2.434. All P <0.05). After 3 months and 6 months, the NIHSS score was significantly higher in the treatment group compared to those in the control group (t = 2.455 and 2.193. All P <0.05).
Conclusion: Mecobalamin can reduce the level of plasma homocysteine, then lead to reductions of levels of plasma inflammatory factors and volume of carotid artery plaques, resulting in more significant functional recovery.[1]
|
| Animal Protocol |
To analyze the effect of mecobalamin on the early-functional outcomes of patients with ischemic stroke and H-type hypertension.
Methods: From October of 2014 to October of 2016, 224 cases of ischemic stroke and H-type hypertension were selected. The patients were randomly divided into treatment control groups, with 112 patients in each group. The control group was treated with the conventional therapy. The observation group was treated with 500 µg of mecobalamin three times a day in addition to the conventional therapy. We compared serum homocysteine (Hcy), hs-CRP levels, carotid plaques, and NIHSS scores between the two groups on the 2nd day and at 4 weeks, 8 weeks, 3 months, and 6 months.[1]
|
| References | |
| Additional Infomation |
Mecobalamin is a synthetic, active form of vitamin B12 that crosses the blood-brain barrier without biotransformation. It can be used to treat or prevent vitamin B12 deficiency and its complications. After taking Mecobalamin, it replenishes endogenous vitamin B12, increases vitamin B12 levels, and improves vitamin B12 deficiency. Vitamin B12 is essential for hematopoiesis, nerve metabolism, DNA and RNA synthesis, and the metabolism of carbohydrates, fats, and proteins. It improves the function of iron in metabolic cycles and assists in the synthesis of choline from folic acid. Its metabolism is closely related to folic acid metabolism.
See also: Mecobalamin (note moved here). |
| Molecular Formula |
C63H92CON13O14P
|
|---|---|
| Molecular Weight |
1345.3903
|
| Exact Mass |
1343.587
|
| Elemental Analysis |
C, 56.28; H, 6.82; Co, 4.38; N, 13.54; O, 16.66; P, 2.3
|
| CAS # |
13422-55-4
|
| Related CAS # |
288315-09-3
|
| PubChem CID |
60196341
|
| Appearance |
Brown to red solid powder
|
| Melting Point |
>190°C (dec.)
|
| LogP |
7.199
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
20
|
| Rotatable Bond Count |
26
|
| Heavy Atom Count |
92
|
| Complexity |
3140
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[CH3-].CC1=CC2=C(C=C1C)N(C=N2)C3C(C(C(O3)CO)OP(=O)([O-])OC(C)CNC(=O)CCC\4(C(C5C6(C(C(C(=N6)/C(=C\7/C(C(C(=N7)/C=C\8/C(C(C(=N8)/C(=C4\[N-]5)/C)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N)/C)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)C)O.[Co+3]
|
| InChi Key |
ZFLASALABLFSNM-UHFFFAOYSA-L
|
| InChi Code |
InChI=1S/C62H90N13O14P.CH3.Co/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);1H3;/q;-1;+3/p-2
|
| Chemical Name |
carbanide;cobalt(3+);[5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] 1-[3-[(4Z,9Z,14Z)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7,12,17-tetrahydro-1H-corrin-21-id-3-yl]propanoylamino]propan-2-yl phosphate
|
| Synonyms |
DTXSID5048631; Algobaz; CH3-B12; Methylcobalamin, Cobaday, MBL-A, Mecobalamin, Cobalt-methylcobalamin, Cobamet, Cobametin, E0302, Methycobal, Methyl b12, Methyl cobalamine, Methyl vitamin B12, Methyl-B12, Vancomin; Mecobalamin; methylcobalamin; NCGC00188434-01; 13422-55-4
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7433 mL | 3.7164 mL | 7.4328 mL | |
| 5 mM | 0.1487 mL | 0.7433 mL | 1.4866 mL | |
| 10 mM | 0.0743 mL | 0.3716 mL | 0.7433 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT07423390
Conditions:Peripheral Neuropathy Due to Chemotherapy|Peripheral Neuropathy, Chemotherapy-inducedLink: https://clinicaltrials.gov/ct2/show/NCT07133438
Conditions:Retinal Vein Occlusion (RVO)Link: https://clinicaltrials.gov/ct2/show/NCT07344974
Conditions:Breast Cancer
Title:Mecobalamin in Promoting Recurrent Laryngeal Nerve Function Recovery After Thyroid Surgery
Status:Not yet recruiting
updateDate:2025-12-10
Ctid:NCT07274696
Link: https://clinicaltrials.gov/ct2/show/NCT07274696
Conditions:Patients Undergoing Open Thyroid SurgeryLink: https://clinicaltrials.gov/ct2/show/NCT06813274
Conditions:Diabetes Mellitus|Diabetic Retinopathy|Cognitive Impairment|Neurovascular CouplingLink: https://clinicaltrials.gov/ct2/show/NCT03548311
Conditions:Amyotrophic Lateral SclerosisLink: https://clinicaltrials.gov/ct2/show/NCT05008042
Conditions:FibromyalgiaLink: https://clinicaltrials.gov/ct2/show/NCT05785585
Conditions:Vitamin B12 Nutritional DeficiencyLink: https://clinicaltrials.gov/ct2/show/NCT06220929
Conditions:Sepsis|Liver DysfunctionLink: https://clinicaltrials.gov/ct2/show/NCT04800666
Conditions:Peripheral Facial PalsyLink: https://clinicaltrials.gov/ct2/show/NCT05623384
Conditions:Sudden DeafnessLink: https://clinicaltrials.gov/ct2/show/NCT05184049
Conditions:DiabetesLink: https://clinicaltrials.gov/ct2/show/NCT03485404
Conditions:Post Operative Cognitive DysfunctionLink: https://clinicaltrials.gov/ct2/show/NCT03593304
Conditions:Vincristine Induced Neurotoxicity|Acute Lymphoblastic LeukaemiaLink: https://clinicaltrials.gov/ct2/show/NCT04372316
Conditions:Diabetic NeuropathiesLink: https://clinicaltrials.gov/ct2/show/NCT02923388
Conditions:Vincristine Induced Peripheral Neuropathy (VIPN)Link: https://clinicaltrials.gov/ct2/show/NCT00273650
Conditions:Autistic DisorderLink: https://clinicaltrials.gov/ct2/show/NCT03983200
Conditions:Diabetic Peripheral NeuropathyLink: https://clinicaltrials.gov/ct2/show/NCT00165711
Conditions:Dementia With Vitamin B12 DeficiencyLink: https://clinicaltrials.gov/ct2/show/NCT02540642
Conditions:Type 2 Diabetes|Vitamin B12 Deficiency|HyperhomocysteinemiaLink: https://clinicaltrials.gov/ct2/show/NCT03167918
Conditions:Type 2 Diabetes Mellitus|Pulmonary FunctionLink: https://clinicaltrials.gov/ct2/show/NCT02853942
Conditions:Injury of Facial Nerve, Unspecified Side, Initial EncounterLink: https://clinicaltrials.gov/ct2/show/NCT00692315
Conditions:Autistic DisorderLink: https://clinicaltrials.gov/ct2/show/NCT01661309
Conditions:Vitamin B12 DeficiencyLink: https://clinicaltrials.gov/ct2/show/NCT00699478
Conditions:Vitamin B12 DeficiencyProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
